Skip to main content

Advertisement

Fig. 3 | Clinical and Translational Medicine

Fig. 3

From: PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma

Fig. 3

Add-on compounds to reverse the dexamethasone insensitivity of PBMCs in severe asthma. a The inhibition of IL8 release in PBMCs of normal subjects when compound was added to dexamethasone (0.01 μM, 0.1 μM, and 1 μM) treated medium. b The inhibition of IL8 release in PBMCs of mild/moderate asthma when compound was added to dexamethasone (0.01 μM, 0.1 μM, and 1 μM) treated medium. c The inhibition of IL8 release in PBMCs of severe asthma when compound was added to dexamethasone (0.01 μM, 0.1 μM, and 1 μM) treated medium (IL-8 releasing level is relative to the level of group without dexamethasone treatment. *p < 0.05, PI3K inhibitor added group compared with PBS added group. ns: no significant difference, PI3K inhibitor added group compared with PBS added group)

Back to article page